The US Food and Drug Administration is advising that certain extended-release formulations of metformin made by five manufacturers have high levels of the potential carcinogen N-Nitrosodimethylamine (NDMA) and has requested these products be recalled. Earlier evaluations led the agency to conclude these products posed negligible cancer risks.
Valisure, the online pharmacy that challenged the agency's initial test findings, asserts that the FDA continues to underestimate the carcinogenic risks in metformin drugs and needs better testing methods to evaluate these risks
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?